Literature DB >> 9633836

Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients.

C L Cazzullo1, M Saresella, K Roda, M G Calvo, P Bertrando, S Doria, M Clerici, A Salvaggio, P Ferrante.   

Abstract

Peripheral blood (PB) lymphocyte subpopulations, IgG, IgM, IgA and IgE serum immunoglobulins and C3 and C4 complement fractions were evaluated in 29 schizophrenic patients, 31 of their relatives and 20 healthy subjects. The patients fulfilled DSM-III criteria for schizophrenia, and were unmedicated for 3 months prior to the PB sample collection. When compared to healthy controls and their own relatives, the schizophrenic patients showed a lower level of CD4+ cells, while the CD4+ 45RA+ (naive) subset was significantly higher. Conversely, the number of CD4+ 45RA- (memory) lymphocytes was significantly lower in schizophrenic patients in comparison to their relatives and controls, while the CD8+ supressor/cytotoxic T-cell percentage was significantly higher. No significant differences were observed for the IgG, IgM, IgA, IgE and C3 and C4 complement fraction levels among the three groups. The present data confirm the presence of immunological abnormalities in schizophrenic patients and suggest a possible role of environmental factors in the triggering of an autoimmune pathogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633836     DOI: 10.1016/s0920-9964(97)00153-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

Review 1.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

Review 2.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

3.  Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia.

Authors:  H Karlsson; S Bachmann; J Schröder; J McArthur; E F Torrey; R H Yolken
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 4.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

Review 5.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

6.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

7.  The Potential Use of Peripheral Blood Mononuclear Cells as Biomarkers for Treatment Response and Outcome Prediction in Psychiatry: A Systematic Review.

Authors:  Jobbe Goossens; Manuel Morrens; Violette Coppens
Journal:  Mol Diagn Ther       Date:  2021-05-12       Impact factor: 4.074

8.  A fundamental bimodal role for neuropeptide Y1 receptor in the immune system.

Authors:  Julie Wheway; Charles R Mackay; Rebecca A Newton; Amanda Sainsbury; Dana Boey; Herbert Herzog; Fabienne Mackay
Journal:  J Exp Med       Date:  2005-12-05       Impact factor: 14.307

9.  Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms.

Authors:  Rachel M Craddock; Helen E Lockstone; David A Rider; Matthew T Wayland; Laura J W Harris; Peter J McKenna; Sabine Bahn
Journal:  PLoS One       Date:  2007-08-01       Impact factor: 3.240

10.  Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.

Authors:  Emilio Fernandez-Egea; Petra E Vértes; Shaun M Flint; Lorinda Turner; Syed Mustafa; Alex Hatton; Kenneth G C Smith; Paul A Lyons; Edward T Bullmore
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.